- Details
- (Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...
|
- Details
- (Length of discussion - 8 minutes) Approximately 25% of testicular cancer patients present with advanced stage disease. Once chemotherapy is administered, radiologically-detectable residual masses are found in about 60% of these patients, making it difficult for a clinician to diagnose residual disease versus fibrosis or necrosis. Long-term survivable rates for these patients is generally favorabl...
|
- Details
- Professor Anwar Padhani discusses the value of whole body MRI scanning in diagnosing disease progression at the Radiological Society of North America (RSNA) 2017 conference. Dr. Padhani discusses the biggest advantage of using whole body MRI scanning versus bone or CT scans, which is the ability to detect metastatic disease in bone. Whole body MRI scans are also accurate in detecting castrate-resi...
|
- Details
- Dr. Baris Turkbey, Associate Research Physician of the Molecular Imaging Program at the National Cancer Institute, shares the past, present, and future approaches to prostate biopsies. Dr. Turkbey states that TRUS (Transrectal Ultrasound aka Systemic) biopsies have been the “standard of care” after PSA elevation for the past 25 years. However, prostate imaging is not always preceding biopsy. MRI p...
|
- Details
- (Length of discussion - 9 minutes) Dr. Jelle Barentsz provides his perspective on treating a patient with a rising PSA and is seeking diagnosis options. During this discussion held at the Radiological Society of North America (RSNA) 2017 conference, he shares that he would not recommend a 12-core systematic biopsy because it is not targeted. 40% of patients with a trans-rectal ultrasound guided (T...
|
- Details
- 18F-Fluciclovine PET/CT Scanning in Patients With High Risk Primary Prostate Carcinoma - Trond Bogsrud (Length of discussion - 10 minutes) Dr. Trond Bogsrud discusses the performance of the investigational amino acid PET tracer fluciclovine F18 compared to histopathology which was retrospectively evaluated in patients with high risk primary prostate carcinoma to investigate whether fluciclovine F1...
|
- Details
- (Length of Presentation: 9 min) Jens Sorensen, MD presents on the topic of the prognostic value of 11C-Acetate PET/CT. 11 C-Acetate PET/CT is strongly linked to the aggressiveness of prostate cancer (PCa) under experimental conditions. 11 C-Acetate PET/CT is a potential noninvasive biomarker of malignant lipogenesis in PCa, but its prognostic value is not known. The objective of this study was to...
|
- Details
- David Crawford, MD discusses with Thomas Keane, MD, the paper, RADAR II: The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer, which was designed to offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostat...
|
- Details
- Imaging Controversies for Assessing Localized and Advanced PCa, an Interview with Charles Ryan and Phillip Koo Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of interview: 6 min) Dr. Phillip Koo talks with Charles Ryan, MD about imaging controversies when it comes to local and metastatic disease. He overviews his LUGPA 2017 presentation on local disease in a practical and c...
|
- Details
- (Length of lecture ~ 8 minutes) Prostate-specific membrane antigen (PSMA) is over-expressed in prostate cancer, so it is a good target to use for diagnoses and treatment. 18F-DCFBC binds to the external domain of PSMA, so when it is used as a PET tracer it can be very helpful in improving imaging of localized and metastatic prostate cancer. The goal of this research is to asses the ability of 18F-...
|
